Aiming to IgE: Drug development in allergic diseases

Area of Science:

• Immunology
• Allergy Research
• Therapeutic Strategies

Background:

• Allergic diseases like dermatitis, rhinitis, asthma, and food allergies are increasing worldwide, posing a significant public health challenge.
• Immunoglobulin E (IgE) plays a central role in mediating common allergic diseases through interactions with its high-affinity receptor (FcεRⅠ) on mast cells and basophils, and its low-affinity receptor (CD23).

Purpose of the Study:

• To review current therapeutic strategies aimed at interfering with immunoglobulin E (IgE) in the management of allergic diseases.
• To explore novel approaches, including targeting memory B cells, for more effective control of allergic conditions.

Main Methods:

• Comprehensive review of existing literature on IgE-mediated allergic diseases and current therapeutic interventions.
• Analysis of the mechanisms underlying IgE's role in allergic responses and immune cell regulation.
• Discussion of emerging strategies focusing on memory B cells and multi-target drug development.

Main Results:

• IgE interacts with FcεRⅠ and CD23, initiating signaling cascades that lead to mast cell and basophil activation and regulating immune responses.
• Various therapeutic strategies targeting IgE are under development and gaining attention for allergic disease treatment.

Conclusions:

• Targeting memory B cells, including long-lived plasma cells and IgE+ memory B cells, may offer a pathway to complete control of allergic diseases.
• Developing drugs with synergistic effects on multiple targets is a promising approach to enhance treatment efficacy for systemic allergic disorders.